Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

How to optimize current treatment of genotype 2 hepatitis C virus infection.

Marciano S, Gadano AC.

Liver Int. 2014 Feb;34 Suppl 1:13-7. doi: 10.1111/liv.12399. Review.

PMID:
24373073
2.

Treatment of hepatitis C virus genotype 3-infection.

Pol S, Vallet-Pichard A, Corouge M.

Liver Int. 2014 Feb;34 Suppl 1:18-23. doi: 10.1111/liv.12405. Review.

PMID:
24373074
3.

Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?

Serfaty L.

Liver Int. 2014 Feb;34 Suppl 1:11-2. doi: 10.1111/liv.12407. Review.

PMID:
24373072
4.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
5.

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR.

Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744.

PMID:
22006408
6.

Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.

Esmat G, El Kassas M, Hassany M, Gamil M, El Raziky M.

Liver Int. 2014 Feb;34 Suppl 1:24-8. doi: 10.1111/liv.12397. Review.

PMID:
24373075
7.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
9.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

10.

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.

Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, Tsuda Y, Steinmann G, Omata M.

Liver Int. 2014 Jan;34(1):78-88. doi: 10.1111/liv.12254. Epub 2013 Aug 15.

PMID:
23944720
11.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
12.

Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.

Moore CM, George M, Van Thiel DH.

Dig Dis Sci. 2011 Oct;56(10):3032-7. doi: 10.1007/s10620-011-1869-6. Epub 2011 Aug 31.

PMID:
21879283
13.

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Shiffman ML, Benhamou Y.

Liver Int. 2013 Feb;33 Suppl 1:105-10. doi: 10.1111/liv.12066. Review.

PMID:
23286853
14.

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.

Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30.

PMID:
21987462
15.

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.

Gill U, Aziz H, Gill ML.

Int J Infect Dis. 2013 Nov;17(11):e1017-21. doi: 10.1016/j.ijid.2013.05.012. Epub 2013 Jul 27.

16.

How to optimize HCV therapy in genotype 2 patients.

Grassi E, Aghemo A.

Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056. Review.

PMID:
23286844
17.

Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.

Mira JA, García-Rey S, Rivero A, de los Santos-Gil I, López-Cortés LF, Girón-González JA, Téllez F, Márquez M, Merino D, Ríos-Villegas MJ, Macías J, Rivero-Juárez A, Pineda JA.

Clin Infect Dis. 2012 Dec;55(12):1719-26. doi: 10.1093/cid/cis779. Epub 2012 Sep 5.

18.

Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.

Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B; CORAL-2 study group.

Antivir Ther. 2011;16(6):833-41. doi: 10.3851/IMP1837.

PMID:
21900715
19.

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597.

PMID:
23918536
20.

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP.

Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067. Review.

PMID:
23286846
Items per page

Supplemental Content

Write to the Help Desk